Home Journals Articles Updates About
CN
image
收藏切换
Efficacy and Safety Analysis of PD-1 Inhibitors in Elderly Patients with Advanced Non-small Cell Lung Cancer
收藏切换
PDF
Yunhui ZHANG1, Luhua ZHONG1, Huanjun HUANG1, Chenchen GUO2, Xinyi DONG2, Feng SHI2, Zhuojia CHEN1, Weiting LIANG1, *
Pharmacy Today | 2025, 35(8) : 609 - 613
Less
收藏切换
Pharmacy Today | 2025, 35(8): 609-613
Efficacy and Safety Analysis of PD-1 Inhibitors in Elderly Patients with Advanced Non-small Cell Lung Cancer
Full
Yunhui ZHANG1, Luhua ZHONG1, Huanjun HUANG1, Chenchen GUO2, Xinyi DONG2, Feng SHI2, Zhuojia CHEN1, Weiting LIANG1, *
Affiliations
  • 1.Department of Pharmacy, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, China
  • 2.School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, Guangdong 510006, China
Published: 2025-08-25 doi: 10.12048/j.issn.1674-229X.2025.08.009
Outline
收藏切换
OBJECTIVE

To investigate the efficacy and safety of programmed death protein 1 (PD-1) inhibitors in elderly patients with advanced non-small cell lung cancer (NSCLC) in a real-world setting.

METHODS

The medical records of 103 patients with advanced NSCLC who received PD-1 inhibitors from January 1, 2020 to January 1, 2023 were retrospectively analyzed 103 patients with advanced NSCLC to compare the objective response rate (ORR), disease control rate (DCR), and adverse drug reaction (ADR) incidence rates among patients aged 65 to 74 years and those 75 years and older.

ESULTS

The ORR for the 65-74 age group (n=93) and ≥75 years group (n=10) was 44.09% and 40.00%, respectively. DCR was 83.87% and 90.00%, respectively. The overall incidence of ADR was 95.70% and 100.00%, and the incidence of grade ≥3 ADR was 18.28% and 20.00%. No statistically significant differences were observed between groups.

CONCLUSION

Elderly patients with advanced NSCLC receiving PD-1 inhibitors showed similar efficacy and safety between 65-74 years and ≥75 years. However, given the small sample size in the ≥75 years group, these preliminary results warrant further validation through large-scale, prospective studies.

programmed death protein 1inhibitor  /  non-small cell lung cancer  /  elderly patients  /  efficacy  /  safety
Yunhui ZHANG, Luhua ZHONG, Huanjun HUANG, Chenchen GUO, Xinyi DONG, Feng SHI, Zhuojia CHEN, Weiting LIANG. Efficacy and Safety Analysis of PD-1 Inhibitors in Elderly Patients with Advanced Non-small Cell Lung Cancer[J]. Pharmacy Today, 2025 , 35 (8) : 609 -613 . DOI: 10.12048/j.issn.1674-229X.2025.08.009
Appendix
Less
Year 2025 volume 35 Issue 8
PDF
273
127
Cite this Article
BibTeX
Article Info
doi: 10.12048/j.issn.1674-229X.2025.08.009
  • Receive Date：2024-08-30
  • Online Date：2026-02-11
  • Published：2025-08-25
Article Data
Affiliations
History
  • Received：2024-08-30
Funding
Affiliations
    1.Department of Pharmacy, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, China
    2.School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, Guangdong 510006, China
References
Share
https://castjournals.cast.org.cn/joweb/jryx/EN/10.12048/j.issn.1674-229X.2025.08.009
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family		 属数
Number of
genus		 种数
Number of
species		 占总种数比例
Percentage of
total species (%)		 属
Genus		 种数
Number of
species		 占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT
Links
Articles
Latest Articles
Most Read
Collections
Updates
Events
News
Multimedia
About
About Us
Contact
No. 86 Xueyuan South Road, Haidian District, Beijing
100081
010-62199257
qkjq@cast.org.cn

Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House